ContractField-of-Use Non-Exclusive License Agreement • August 16th, 2012 • Globeimmune Inc • Pharmaceutical preparations • Washington
[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Amendment to the Field-Of-Use Non-Exclusive License Agreement for Yeast-Based Delivery Vehicles Between Washington Research Foundation and GlobeImmune, Inc.Field-of-Use Non-Exclusive License Agreement • July 2nd, 2012 • Globeimmune Inc • Pharmaceutical preparations
This Amendment to Field-Of-Use Non-Exclusive License Agreement For Yeast-Based Delivery Vehicles Between Washington Research Foundation and GlobeImmune, Inc. (the “Amendment”) is entered into by Washington Research Foundation (“WRF”), a non-profit Washington Corporation, having administrative offices at 2815 Eastlake Avenue East, Suite 300, Seattle, Washington U.S.A. 98102, and GlobeImmune, Inc. (“GLOBEIMMUNE”), a corporation organized under the laws of Delaware, having its principal office at 1450 Infinite Drive, Louisville, CO 80027, and is effective as of the day of the last of the PARTIES to sign (the “Amendment Date”).
